1. Introduction {#sec1}
===============

Most cases of influenza A(H1N1)pdm09 infection have a mild outcome; however some present as severe acute respiratory infection (SARI) and require admission to intensive care unit (ICU) \[[@B1], [@B2]\]. The main reason for admission to ICU is a pulmonary inflammatory syndrome characterized by diffuse alveolar damage (acute respiratory distress syndrome: ARDS), which can be fatal. Since the beginning of 2009 pandemic, international health authorities recommended monitoring severe and complicated cases of influenza infection \[[@B3], [@B4]\]. Considering the serious outcome of these respiratory diseases, the contribution of other respiratory pathogens besides A(H1N1)pdm09 should be envisaged \[[@B5]\]. Additionally, in clinical practice, a specific causative agent which explains the respiratory symptoms is often unidentified, owing to the lack of sensitive tests or the presence of an as-yet unknown pathogen. The recently developed VIDISCA-454 (*VIrus DIScovery using CDNA Amplified fragment-length polymorphism* combined with*Roche-454* high-throughput sequencing) is a sensitive sequence-independent virus discovery technique which can be used to reveal as-yet unknown viruses \[[@B5], [@B6]\].

This study aimed at evaluating the proportion of SARI/ARDS cases and deaths due to A(H1N1)pdm09 infection and assessing the impact of other respiratory pathogens during pandemic and postpandemic period (2009--2011) in northern Italy as well as searching for unknown viruses in those cases for which diagnosis remained negative. To this end, common respiratory pathogens were investigated and VIDISCA-454 methodology was applied on samples which remained negative for all tested pathogens.

2. Materials and Methods {#sec2}
========================

In the capacity of reference laboratory operating within InfluNet network \[[@B7]\], our laboratory is in charge of carrying out the virological surveillance of severe forms of influenza infection in Lombardy (nearly 10 million inhabitants). From October 1, 2009, to April 30, 2011, 206 respiratory samples were collected from patients hospitalized due to severe respiratory illness. Of these, 61.2% were males with a median age of 44.3 years (IQR: 49.7 years; range: 1 month--89 years); 17.5% were children ≤ 5 years and 23.3% were ≥65 years. Data on comorbidities presence were available for nearly 70% of study patients: 64.3% reported medical conditions \[[@B3], [@B4]\]; in detail, 25.6% had weakened immune system (due to cancer, HIV/AIDS, or long-term steroid treatment), 19.7% heart disease, 11.6% asthma/chronic lung disease, and 10.4% neurological/neurodevelopmental conditions. Out of 206 patients, 91 (59.3% males; 18.7% aged ≤ 5 years, 58.2% aged 6--64 years) were SARI cases who required admission to ICU and extracorporeal membrane oxygenation (ECMO) therapy, and 115 (62.6% males; 16.5% aged ≤5 years, 60% aged 6--64 years) were ARDS cases, as defined by the European Consensus Conference \[[@B8]\]. Nine ARDS patients (median age: 35.6 years, IQR: 21.4 years) died during hospitalization: case fatality rate (CFR) in our ARDS series was 7.8% (9/115). No SARI case was fatal.

Respiratory specimens (paired nasal/oral swab and bronchoalveolar lavage) were collected from each SARI/ARDS case. Nucleic acids were purified by*NucliSENS easyMAG* (*bioMérieux,* France) and analyzed by real-time RT-PCR assay to identify influenza virus. In detail, a one-step real-time RT-PCR assay was performed to simultaneously detect influenza viruses type A and B \[[@B9]\]. The subtyping of influenza A positive samples was carried out by a one-step real-time RT-PCR assay using specific primer/probe sets for the hemagglutinin gene \[[@B10]\].

The clinical specimens that resulted negative to influenza virus detection were then screened by real-time RT-PCR/PCR for a panel of respiratory pathogens (*Respiratory MWS r-gene Real-time PCR, bioMérieux*, France) to detect respiratory syncytial virus (RSV) A and B; human metapneumovirus (hMPV) A and B; human rhinovirus (hRV) and enterovirus (hEV); adenovirus (AdV); human bocavirus (hBoV) 1--4; human coronavirus (hCoV) 229E, NL63, OC43, HKU1; human parainfluenza virus (hPIV) 1--4;*Chlamydophila pneumoniae; Mycoplasma pneumoniae.*

Cases which resulted negative to all diagnostic assays were further investigated by VIDISCA-454 technique. This is a virus discovery method based on recognition of restriction enzyme cleavage sites, ligation of adaptors, and subsequent amplification by PCR combined with high-throughput sequencing 454 FLX/Titanium system (Roche, USA) \[[@B5]\].

3. Results {#sec3}
==========

Influenza A(H1N1)pdm09 virus was detected in 58.3% (120/206) of SARI/ARDS cases (61.7% males; 13.3% aged ≤ 5 years, 67.5% aged 6--64 years). Moreover, the presence of another condition possibly increasing the risk for developing influenza-related complications \[[@B3], [@B4]\] was acknowledged for nearly half of A(H1N1)pdm09-positive SARI/ARDS cases: 25.4% had weakened immune system, 15.2% had heart disease, 11.9% were morbidly obese people (body mass index ≥ 40), 10.2% had asthma/chronic lung disease or neurological/neurodevelopmental conditions, and 4.2% were pregnant women. Approximately half (62/120: 51.7%) of A(H1N1)pdm09-positive patients had ARDS. It is worth mentioning that A(H1N1)pdm09 was identified in 77.8% (7/9) of fatal ARDS cases (42.9% males, median age: 30.4 years, IQR: 15.4 years). Four (4/7: 57.1%) of these individuals belonged to risk categories (i.e., two were cancer patients, one was morbidly obese, and one had underlying neurodevelopmental conditions). Thus, the A(H1N1)pdm09 CFR was 11.3% (7/62).

The impact of respiratory pathogens other than A(H1N1)pdm09 was 19.4% (40/206) (65% males; 30% aged ≤ 5 years, 47.5% aged 6--64 years). HRV/hEV were the most frequently identified viruses followed by influenza A(H3N2) virus, accounting for 27.5% (11/40) and 20% (8/40) of infections, respectively ([Table 1](#tab1){ref-type="table"}). No fatal cases were ascribable to pathogens other than A(H1N1)pdm09.

Forty-six (46/206: 22.3%) SARI/ARDS cases (including two fatalities) resulted negative to all diagnostic assays (58.2% males; 18.2% aged ≤ 5 years, 45.4% aged 6--64 years) and were further investigated by VIDISCA-454 \[[@B5], [@B11]\]. VIDISCA-454 revealed no sequence reads that could belong to a novel virus or viral variant in any of the 46 specimens; however it enabled the identification of one case of undiagnosed measles, thus increasing the proportion of cases with a diagnosis to 78.2% (161/206). Hence, the overall proportion of cases with unknown diagnosis was 21.8% (45/206); most (34/45: 75.6%) cases that could not be diagnosed were ARDS and two (2/45: 4.4%) were fatal. [Figure 1](#fig1){ref-type="fig"} summarizes study results.

4. Discussion {#sec4}
=============

During pandemic and postpandemic period, several pathogens cocirculated and were associated to severe respiratory infections; however, influenza A(H1N1)pdm09 virus had the greatest impact (58.3%) in our SARI/ARDS series. More than half (51.7%) of A(H1N1)pdm09 infection resulted in ARDS. It is interesting to note that most (67.5%) severe respiratory diseases due to A(H1N1)pdm09 infection were identified among 6--64-year-old individuals. The A(H1N1)pdm09 case fatality rate in our ARDS series was 11.3% fatal cases in young adults, and 42.8% did not belong to any at-risk category \[[@B3], [@B4]\]. This data is in agreement with other studies; Van Kerkhove et al. have reported a median age of 46 years among fatal laboratory-confirmed A(H1N1)pdm09 cases \[[@B12]\]. McCallum has described that during the 2009 pandemic only 1% of laboratory-confirmed cases and 13% of laboratory-confirmed deaths were among persons 65 years of age or older \[[@B13]\]. The Global Pandemic Mortality (GLaMOR) project has evaluated that although the pandemic mortality estimate was similar in magnitude to that of seasonal influenza, a marked shift toward mortality among persons 65 years of age occurred, so that many more life-years were lost \[[@B14]\]. Such an age shift has been documented as well by several studies on A(H1N1)pdm09 mortality \[[@B15]--[@B17]\].

The proportion of SARI/ARDS cases associated with respiratory viruses other than A(H1N1)pdm09 was significantly lower (19.4% versus 58.3%, *P* value \<0.0000001). Severe respiratory diseases associated with respiratory viruses other than A(H1N1)pdm09 were detected more frequently among children ≤ 5 years (13.3% versus 30%, *P* value = 0.02). This piece of evidence is in accordance with the results of other studies reporting a notable burden of respiratory viruses in children under 5 years \[[@B18]--[@B20]\].

Studies published to date have suggested that influenza viruses and rhinoviruses are the leading causes of severe respiratory disease leading to hospitalization \[[@B21], [@B22]\], similarly to what was observed in our SARI/ARDS series, where hRV/hEV were the most common identified viruses along with influenza viruses. Also influenza A(H3N2) virus played a significant role in our SARI cases and caused ARDS in one patient with a weakened immune system due to HIV/AIDS. Overall, the proportion of SARI/ARDS correlated to an influenza A virus infection was 62.1% (128/206), thus emphasizing the central role of influenza A virus in severe respiratory infection \[[@B23], [@B24]\].

The use of molecular assay has notably contributed to identifying pathogens possibly involved in severe respiratory disease, thus allowing getting to a diagnosis of viral infection in nearly 80% of study SARI/ARDS cases. Other studies that have not used nucleic acid amplification assays have typically reported that 5--20% of cases of acute respiratory infection have a viral etiology \[[@B25]\]. In addition, it is noteworthy that VIDISCA-454 enabled the identification of one measles infection that escaped clinical diagnosis in one SARI case. Hence, measles infection should be considered in complicated pulmonary disease, as also suggested by others \[[@B26]\], since measles virus is not generally included in respiratory diagnostic panels.

5. Conclusions {#sec5}
==============

During pandemic and postpandemic period, several pathogens cocirculated and were associated to severe respiratory infections, with influenza A(H1N1)pdm09 virus having the greatest impact. Nearly 22% of SARI/ARDS cases did not obtain a definite diagnosis, and among these cases two were fatal. In clinical practice, great efforts should be devoted to improving diagnosis of severe respiratory infections and to reducing such "diagnostic gap." The advantage from relying upon more accurate diagnosis could benefit the patient, in terms of receiving the more appropriate antiviral drugs, and could provide more detailed information on viruses circulating in the community, thus making public health authorities aware so as to adjust their policies accordingly.

VIDISCA-454 proved to be a sensitive and specific methodology that can be successfully applied to surveillance of viral respiratory infections that represent an ever-changing field due to the continuous emergence of new viruses (i.e., influenza A(H5N1) and A(H7N9) viruses, MERS-CoV).

This study was funded by Grant no. 5988, 30/6/2011 from Direzione Generale Sanità, Regione Lombardia, and by the European Community\'s Seventh Framework Programme (FP7/2007--2013) under EMPERIE project, EC Grant agreement no. 223498.

Conflict of Interests
=====================

The authors declare that there is no conflict of interests regarding the publication of this paper.

![Study design and results overview.](BMRI2014-241298.001){#fig1}

###### 

Impact of respiratory pathogens on the patients with SARI/ARDS (*N* = 206).

  Pathogen                       Number of positive samples        
  ------------------------------ ---------------------------- ---- -----
  Influenza A(H1N1)pdm09 virus   58                           62   120
  hRV/hEV                        7                            4    11
  Influenza A(H3N2) virus        7                            1    8
  RSV                            3                            1    4
  hCoV                           2                            2    4
  hPIV                           2                            2    4
  AdV                            2                            0    2
  Influenza B virus              1                            0    1
  hBoV                           1                            0    1
  hMPV                           0                            0    0
  *Chlamydophila pneumoniae*     0                            0    0
  *Mycoplasma pneumoniae*        0                            0    0
                                                                   
  Coinfections                   2                            3    5
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